Endpoints News
AstraZeneca follows Lilly and Merck in reconsidering UK site Read in browser
Endpoints News
Thank you for reading, dupa dupackia!
basic
UPGRADE
Mon T W Th F
15 September, 2025
Health Tech Day 2025
Health tech is attracting capital and defying the downturn: from wearable tech to RWE, momentum is building. Join our online session in the AM and in the PM we’re live in person that evening with a reception at NYC’s Book Club Bar. Don’t miss out — seats are limited, get your spot.
news
Novartis extends deal spree with $120M for Monte Rosa's immune degraders
ENDPOINTS NEWS
Exclusive: Lila Sciences is closing in on $300M+ fundraise at $1B+ valuation, to scale up its bet on autonomous science
ENDPOINTS NEWS
AstraZeneca pauses $271M investment in UK, following Merck and Lilly moves
ENDPOINTS NEWS
Exclusive: A first-time CEO launches startup to bring AI into the lab
ENDPOINTS NEWS
Endpoints webinars
Sep 23
11:00am ET
Data you can trust: Setting the bar for ML/LLM-extracted real-world data
Flatiron
Sep 25
11:00am ET
Speed meets precision: Unlocking high-parameter flow cytometry with acoustic focusing
Thermo Fisher
Oct 02
10:30am ET
Unlocking patient access: Modernizing clinical trial regulatory frameworks and trial delivery
Lilly
Oct 21
11:00am ET
AI in life sciences: Reimagining teams, technology and partnerships for the future
Zaidyn by ZS
GLOBAL PHARMA AND BIOTECH SUMMIT - Embracing and industry reset
Biopharma is grappling with diverging policies between the US, EU, and Asia — including proposed drug pricing reforms in the US and new EU regulations taking effect this year. The need for strategic clarity has never been more urgent. Join us in London — in person and virtually — where we’re bringing together the industry’s most influential voices to chart a path forward.
in case you missed it
1.
Pfizer has a VEGF bispecific strategy. And it’s very different than Summit’s
ENDPOINTS NEWS
2.
Top drug regulator pushes back on report that FDA wants to 'abandon' some adcomms
ENDPOINTS NEWS
3.
Lilly loses bid to overturn $183.7M judgment in Medicaid rebate fight
ENDPOINTS NEWS
4.
Peer Review
Ousted FDA official joins Lilly; Novo names global research head as layoffs come into focus
ENDPOINTS NEWS
5.
KalVista reports strong sales in early launch of hereditary angioedema drug
ENDPOINTS NEWS
6.
Lilly’s UK Gateway Labs plans are up in the air in latest blow to region's biopharma industry
ENDPOINTS NEWS
7.
News Briefing
A new biotech fund in the Middle East; Xspray preps for FDA decision on Dasynoc
ENDPOINTS NEWS
8.
Trump Is Shutting Down the War On Cancer
THE NEW YORK TIMES
Elizabeth Cairns
.

Endpoints had an exciting exclusive over the weekend, with Andrew Dunn reporting that the AI company Lila Sciences will soon finalize an about $300 million Series A raise. Read his piece here.
.
Elizabeth Cairns
Senior Biopharma Journalist, Endpoints News